Details for synthetic oligopeptides and results with the MHC stabilization assay
Peptide no. . | Amino acid sequence . | Protein name . | Start position . | Amino acid length . | Score* . | Percentage MFI increase† . |
---|---|---|---|---|---|---|
1 | FYNIPPMPL | EBNA2 | 282 | 9 | 300 | 390 |
2 | GYDVGHGPL | EBNA2 | 119 | 9 | 200 | 44 |
3 | DYMAIHRSL | EBNA3A | 271 | 9 | 420 | 142 |
4 | VYDSMLQSDL | EBNA3B | 114 | 10 | 240 | 66 |
5 | RYEDPDAPL | EBNA3C | 721 | 9 | 720 | 41 |
6 | GYQEPPAHGL | EBNA3C | 775 | 10 | 360 | 36 |
7 | DYSQGAFTPL | EBNA3C | 923 | 10 | 240 | 72 |
8 | DYDASTESEL | EBNA3C | 982 | 10 | 220 | 40 |
9 | RYAREAEVRF | EBNA3C | 239 | 10 | 200 | 80 |
10 | GYRTATLRTL | EBNA3C | 183 | 10 | 200 | 40 |
11 | IYVLVMLVL | LMP2 | 222 | 9 | 420 | 86 |
12 | SYAAAQRKL | LMP2 | 170 | 9 | 220 | 54 |
13 | LYALALLLL | LMP2 | 357 | 9 | 200 | 213 |
14 | AYRRRWRRL | LMP2 | 234 | 9 | 200 | 46 |
15 | RYCCYYCLTL | LMP2 | 474 | 10 | 400 | 343 |
16 | IYVLVMLVLL | LMP2 | 222 | 10 | 300 | 95 |
17 | SYAAAQRKLL | LMP2 | 170 | 10 | 200 | 60 |
18 | IYLLEMLWRL | LMP1 | 124 | 10 | 300 | 421 |
19 | LYLQQNWWTL | LMP1 | 158 | 10 | 300 | 407 |
20 | AYQAYAAPQL | BZLF1 | 85 | 10 | 300 | 64 |
21 | TYPVLEEMF | BRLF1 | 198 | 9 | 180 | 491 |
22 | DYCNVLNKEF | BRLF1 | 28 | 10 | 132 | 84 |
23 | SYVKQPLCL | BMLF1 | 347 | 9 | 300 | 437 |
24 | DYNFVKQLF | BMLF1 | 320 | 9 | 252 | 221 |
25 | SYKTLREFF | BMLF1 | 230 | 9 | 120 | 265 |
26 | NYNPGTLSSL | BMLF1 | 387 | 10 | 360 | 332 |
27 | SYVKQPLCLL | BMLF1 | 347 | 10 | 300 | 387 |
28 | CYDHAQTHL | BMRF1 | 20 | 9 | 200 | 116 |
29 | TYTSGEACL | BMRF1 | 199 | 9 | 200 | 109 |
30 | FYISLIQGL | BALF2 | 846 | 9 | 432 | 331 |
31 | FYPLATYPL | BALF2 | 25 | 9 | 300 | 547 |
32 | CYENDNPGL | BALF2 | 636 | 9 | 300 | 78 |
33 | TYWQLNQNL | BALF2 | 526 | 9 | 288 | 231 |
34 | LYTGLAQAL | BALF2 | 217 | 9 | 288 | 187 |
35 | AYAEATSSL | BALF2 | 880 | 9 | 240 | 253 |
36 | FYRSLLTIL | BALF2 | 618 | 9 | 240 | 70 |
37 | HYQTLCTNF | BALF2 | 655 | 9 | 180 | 322 |
38 | EYLLGRFSVL | BALF2 | 1035 | 10 | 360 | 72 |
39 | FYMTHGLGTL | BALF2 | 362 | 10 | 300 | 114 |
40 | TYPLREVATL | BALF2 | 30 | 10 | 300 | 83 |
41 | TYWQINQNLL | BALF2 | 526 | 10 | 240 | 270 |
42 | VYAASFSPNL | BALF2 | 407 | 10 | 200 | 244 |
43 | RYSIFFDYM | EBNA3A | 246 | 9 | 60 | 450 |
44 | TYSAGIVQI | EBNA3B | 217 | 9 | 50 | 481 |
45 | TYGPVFMCL | LMP2 | 419 | 9 | 403 | 411 |
46 | RYLRDQQLL | HIV envelope | 584 | 9 | 720 | 251 |
Peptide no. . | Amino acid sequence . | Protein name . | Start position . | Amino acid length . | Score* . | Percentage MFI increase† . |
---|---|---|---|---|---|---|
1 | FYNIPPMPL | EBNA2 | 282 | 9 | 300 | 390 |
2 | GYDVGHGPL | EBNA2 | 119 | 9 | 200 | 44 |
3 | DYMAIHRSL | EBNA3A | 271 | 9 | 420 | 142 |
4 | VYDSMLQSDL | EBNA3B | 114 | 10 | 240 | 66 |
5 | RYEDPDAPL | EBNA3C | 721 | 9 | 720 | 41 |
6 | GYQEPPAHGL | EBNA3C | 775 | 10 | 360 | 36 |
7 | DYSQGAFTPL | EBNA3C | 923 | 10 | 240 | 72 |
8 | DYDASTESEL | EBNA3C | 982 | 10 | 220 | 40 |
9 | RYAREAEVRF | EBNA3C | 239 | 10 | 200 | 80 |
10 | GYRTATLRTL | EBNA3C | 183 | 10 | 200 | 40 |
11 | IYVLVMLVL | LMP2 | 222 | 9 | 420 | 86 |
12 | SYAAAQRKL | LMP2 | 170 | 9 | 220 | 54 |
13 | LYALALLLL | LMP2 | 357 | 9 | 200 | 213 |
14 | AYRRRWRRL | LMP2 | 234 | 9 | 200 | 46 |
15 | RYCCYYCLTL | LMP2 | 474 | 10 | 400 | 343 |
16 | IYVLVMLVLL | LMP2 | 222 | 10 | 300 | 95 |
17 | SYAAAQRKLL | LMP2 | 170 | 10 | 200 | 60 |
18 | IYLLEMLWRL | LMP1 | 124 | 10 | 300 | 421 |
19 | LYLQQNWWTL | LMP1 | 158 | 10 | 300 | 407 |
20 | AYQAYAAPQL | BZLF1 | 85 | 10 | 300 | 64 |
21 | TYPVLEEMF | BRLF1 | 198 | 9 | 180 | 491 |
22 | DYCNVLNKEF | BRLF1 | 28 | 10 | 132 | 84 |
23 | SYVKQPLCL | BMLF1 | 347 | 9 | 300 | 437 |
24 | DYNFVKQLF | BMLF1 | 320 | 9 | 252 | 221 |
25 | SYKTLREFF | BMLF1 | 230 | 9 | 120 | 265 |
26 | NYNPGTLSSL | BMLF1 | 387 | 10 | 360 | 332 |
27 | SYVKQPLCLL | BMLF1 | 347 | 10 | 300 | 387 |
28 | CYDHAQTHL | BMRF1 | 20 | 9 | 200 | 116 |
29 | TYTSGEACL | BMRF1 | 199 | 9 | 200 | 109 |
30 | FYISLIQGL | BALF2 | 846 | 9 | 432 | 331 |
31 | FYPLATYPL | BALF2 | 25 | 9 | 300 | 547 |
32 | CYENDNPGL | BALF2 | 636 | 9 | 300 | 78 |
33 | TYWQLNQNL | BALF2 | 526 | 9 | 288 | 231 |
34 | LYTGLAQAL | BALF2 | 217 | 9 | 288 | 187 |
35 | AYAEATSSL | BALF2 | 880 | 9 | 240 | 253 |
36 | FYRSLLTIL | BALF2 | 618 | 9 | 240 | 70 |
37 | HYQTLCTNF | BALF2 | 655 | 9 | 180 | 322 |
38 | EYLLGRFSVL | BALF2 | 1035 | 10 | 360 | 72 |
39 | FYMTHGLGTL | BALF2 | 362 | 10 | 300 | 114 |
40 | TYPLREVATL | BALF2 | 30 | 10 | 300 | 83 |
41 | TYWQINQNLL | BALF2 | 526 | 10 | 240 | 270 |
42 | VYAASFSPNL | BALF2 | 407 | 10 | 200 | 244 |
43 | RYSIFFDYM | EBNA3A | 246 | 9 | 60 | 450 |
44 | TYSAGIVQI | EBNA3B | 217 | 9 | 50 | 481 |
45 | TYGPVFMCL | LMP2 | 419 | 9 | 403 | 411 |
46 | RYLRDQQLL | HIV envelope | 584 | 9 | 720 | 251 |
Estimated t1/2 of dissociation from the HLA A24 allele (in minutes).
Percentage mean fluorescence intensity (MFI) increase of HLA A∗2402 molecules on T2-A24 cells. Percentage MFI increase = (MFI with sample peptide − MFI without peptide)/(MFI without peptide) × 100. See the MHC stabilization assay section in “Materials and methods.”